Daiichi Sankyo presents new data to support uptake of Lixiana

20 March 2019

Daiichi Sankyo (TYO: 4568) has announced results from the ELIMINATE-AF trial, looking at the safety and efficacy of Lixiana (edoxaban) in people with atrial fibrillation undergoing catheter ablation.

Lixiana, which is also marketed as Savaysa, is an oral, once-daily, factor Xa inhibitor marketed by Daiichi Sankyo and its partners in more than 20 countries around the world.

Daiichi hopes the results from the study, which showed the Lixiana arm had low event rates for both thromboembolic and bleeding events, will support the use of Lixiana in clinical practice.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK